首页|The mTOR pathway in the antiphospholipid syndrome

The mTOR pathway in the antiphospholipid syndrome

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
This perspective discussed the available evidence on the involvement of mTOR pathway in antiphospholipid syndrome(APS),from the aspects of endothelial cells,platelets,monocytes and anti-phospholipid antibodies(PLs),which may lead to future therapeutic applications of mTOR inhibition in APS.

antiphospholipid syndromemTORautoimmune disease

Lanlan Ji、Zhuoli Zhang、Andras Perl

展开 >

Department of Rheumatology and Clinical Immunology,Peking University First Hospital,Beijing,China

Department of Rheumatology and Clinical Immunology,Peking University First Hospital,No.8,Xishiku Street,Beijing 100034,China

Departments of Medicine,Microbiology and Immunology,Biochemistry and Molecular Biology,Division of Rheumatology and Clinical Immunology,State University of New York,UMU,College of Medicine,750 East Adams Street,Syracuse,NY 13210,USA

2023

10.1515/mr-2023-0033

医学评论(英文)

医学评论(英文)

CSTPCD
ISSN：
年,卷(期)：2023.3(6)
  • 18